Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Alpha-GPC (L-alpha-glycerylphosphorylcholine / choline alfoscerate) and ISRIB — mechanism, dosing, side effects, legal status, and pricing.
Alpha-GPC is a non-peptide choline-containing phospholipid derivative that serves as an acetylcholine precursor. It is not FDA-approved in the United States, where it is sold as an unregulated dietary supplement and nootropic ingredient. The compound is marketed as a prescription drug in some countries (e.g., Italy as Gliatilin) for cognitive and vascular disorders, though current regulatory approval status has not been confirmed against primary agency databases. Alpha-GPC is not identified as a WADA-prohibited substance in secondary sources.
ISRIB is a non-peptide small-molecule eIF2B activator (bis-chlorophenoxyacetamide-cyclohexane class) that antagonizes the integrated stress response (ISR) by stabilizing the eIF2B guanine-nucleotide exchange factor complex. It is not an approved drug and has no completed human clinical trials or validated human safety or efficacy data. Chemically distinct eIF2B-activator analogs (DNL343, ABBV-CLS-7262) have reached human trials, but DNL343 missed primary endpoints in a Phase 2/3 ALS trial (January 2025). ISRIB is sold by reagent suppliers for research use only.
Alpha-GPC (L-alpha-glycerylphosphorylcholine / choline alfoscerate)
ISRIB
Category
Legal Status
Mechanism
Dose Range
Route
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Alpha-GPC (L-alpha-glycerylphosphorylcholine / choline alfoscerate)
ISRIB
COA corpus from Disclosed Labs — independently tested batches only.
Alpha-GPC (L-alpha-glycerylphosphorylcholine / choline alfoscerate)
No COA data yet.
Submit testing data →ISRIB
1
COAs
99.8%
Avg purity
1
Labs
Human data: A 12-week randomized controlled trial in 100 subjects with amnestic mild cognitive impairment found 600 mg/day improved ADAS-cog scores by 2.34 points versus placebo with no serious adverse events. A single-blind RCT in 39 healthy volunteers showed 400 mg/day for 2 weeks increased self-reported motivation versus placebo. A small crossover study in 7 resistance-trained men (published only as a conference-supplement abstract) reported a single acute 600 mg dose increased post-exercise growth hormone and peak bench-press force versus placebo. A large retrospective Korean cohort study (n=12,008,977 adults ≥50) found chronic alpha-GPC use associated with elevated 10-year stroke risk (total stroke adjusted HR 1.43, ischemic stroke aHR 1.34) in a dose-dependent pattern. Preclinical: Rat studies showed increased hippocampal acetylcholine release, modulation of choline acetyltransferase/acetylcholinesterase activity in aged rats, attenuation of age-related brain structural changes, and increased hippocampal neurogenesis in seizure models.
Key references
No completed or published human clinical trials of ISRIB itself exist; it has no validated human pharmacokinetic, safety, or efficacy data. In mice, systemic ISRIB enhanced spatial and fear-associated long-term memory in healthy animals, reversed hippocampus-dependent spatial-learning and working-memory deficits weeks after traumatic brain injury, and reset elevated ISR activity in aged (18–24 month) mice, reversing age-related spatial-memory decline with a brief 3-day dosing course. In prion-disease transgenic mice, ISRIB partially restored protein synthesis and prevented neurodegeneration without the pancreatic exocrine toxicity seen with PERK-inhibitor approaches. In vitro and in a patient-derived xenograft mouse model, ISRIB combined with imatinib attenuated RAS/RAF/MAPK and STAT5 signaling and eliminated therapy-resistant chronic myeloid leukemia cells.
Alpha-GPC (L-alpha-glycerylphosphorylcholine / choline alfoscerate) and ISRIB are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Frequency
Dosing Notes
Side Effects
Contraindications
Lab Testing
Key references
Disclosed Labs